Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.
about
Antibody therapies for lymphoma in childrenTargeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureNon-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges AheadMature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BLNon-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescentsDiffuse large B-cell lymphoma in an adolescent male presenting as ureteral stricture.Expression levels of TWIST1 are associated with the clinicopathological stage of B-cell non-Hodgkin lymphoma.Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.Pediatric lymphomas and histiocytic disorders of childhoodChildren's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?International Pediatric Non-Hodgkin Lymphoma Response Criteria.Revised International Pediatric Non-Hodgkin Lymphoma Staging System.Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study ReportAdvances in paediatric cancer treatmentAntibody therapy of pediatric B-cell lymphomaPaediatric non-Hodgkin lymphoma - perspectives in translational biologyRituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group ReportNon-Hodgkin Lymphoma in Children.Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic lHighlights of the third International Conference on Immunotherapy in Pediatric Oncology.Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation.Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection.Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice.Pharmacotherapeutic Management of Pediatric Lymphoma.A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective
P2860
Q24186437-1906D021-23E6-41AB-830E-DC40B28D21CBQ26746934-BA32D2BB-2DE9-4D9C-BC5B-921C7FA2B917Q26797513-2B9EE6E5-A76A-4F99-8C16-83545F7319B0Q30240133-09EFC0F1-2803-47F5-A018-DE1172E8410EQ33709463-5F4E6600-41CA-4FBC-AD4F-A72020110B0BQ33822062-2DC0BE13-BD76-4792-A821-6F58524D4C96Q33908718-7FA5AA05-D1E7-48AB-A824-3913D125D19EQ34292362-86B0E86F-DD20-4C58-AAD8-623682A4974BQ34344942-8F2BA58D-782A-49E2-9589-304908BE8AF0Q34605894-DB151815-39D9-4515-9B88-38CF8DF35595Q35083003-5955AB6E-DF60-438C-AFFB-9191B9CA942CQ35237511-43BCF70A-FEE0-45E0-AAB5-08A4CC9648E8Q35708769-34FD32DB-9ABB-413B-9628-55F27E6655F2Q35708778-9AF75B9D-F1DB-432D-BB32-5FE826278526Q35855211-72892E9C-374A-42F5-9953-7233131B9517Q36508630-D7C33C79-AAA8-495F-BA45-D1CC26D810EEQ36732959-C66D6516-EBC5-47F0-A426-C0D7F83C9447Q36889143-2CD9699E-977F-407F-B1E1-4D0EC0934BAFQ37100817-CDE3DCCF-8A9A-4686-BE31-BECD7EFEF294Q37329442-EFF520CB-8D09-467C-8FE4-A94A5D5E39FFQ38547121-4DA058E0-A574-4952-BA67-4755A0ABBA97Q38687541-B1006CFA-DFF2-4A55-9A39-5815A4D97EC6Q38782141-C4C20D6E-874A-40EC-AC19-6907953A7FB6Q38803361-F508E981-C56C-457A-A87D-2B596DBE4668Q38822525-6693F9E2-948E-46E9-82D6-BF91E6C36010Q38827600-AFFF2AF5-CB18-4771-9CD9-254B2F03FE00Q39403785-F61E508A-0E43-4428-A0AB-88307090F945Q40695241-382ACE83-38C3-4F7D-A605-9AAF862EE9C8Q40912836-4308B4B5-2502-4362-AC65-78FCA58F4049Q42203483-0658B763-A15F-49F8-9EF9-8F76297A4260Q47234653-A10B61D0-1EFC-49E6-8FD9-F15D8AFB34D0Q47951320-E9ADE982-11E0-4F65-936D-A4EE3582AF6DQ48321203-54ACFA42-828B-479C-BA86-E490B4EC6414Q49177202-554ADFB4-CAD5-46B8-B574-94111C95F4B2Q55010628-36F7845D-095E-450B-B5A8-ECDA0A6736CEQ57174502-92A99E03-B59D-43E5-A9D6-2366EF535BA1
P2860
Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Rituximab and FAB/LMB 96 chemo ...... ldren's Oncology Group report.
@ast
Rituximab and FAB/LMB 96 chemo ...... ldren's Oncology Group report.
@en
type
label
Rituximab and FAB/LMB 96 chemo ...... ldren's Oncology Group report.
@ast
Rituximab and FAB/LMB 96 chemo ...... ldren's Oncology Group report.
@en
prefLabel
Rituximab and FAB/LMB 96 chemo ...... ldren's Oncology Group report.
@ast
Rituximab and FAB/LMB 96 chemo ...... ldren's Oncology Group report.
@en
P2093
P2860
P356
P1433
P1476
Rituximab and FAB/LMB 96 chemo ...... ldren's Oncology Group report.
@en
P2093
B Shiramizu
H Weinstein
J R Anderson
L Harrison
S Bergeron
P2860
P2888
P304
P356
10.1038/LEU.2012.255
P50
P577
2012-09-03T00:00:00Z